N/A Completed N=30 Treatment

Training Attention and Eye Movement in ASD

Autistic Disorder · Autism Spectrum Disorder

Source: ClinicalTrials.gov NCT02403817 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2019

Primary outcomePrimary: Spatial Attention Baseline — 80.3; 43.0 Percent Correct

Summary

Current therapies for autism target social and language behaviors, but due to the high-level nature of these skills any improvement rarely extends beyond the targeted behavior. This project uses new technology to implement a novel concept for behavioral intervention to improve basic attention and eye movement skills in ASD. Because these basic skills form the foundation for good social communication, training these abilities has the potential to improve a broad spectrum of clinical symptoms, and in young children may affect the course of development.

Outcome Measures

Outcome	Result	p-value
PRIMARY Spatial Attention Baseline	80.3; 43.0	—
PRIMARY Saccadic Eye Movements Baseline	49.20	—
PRIMARY Change in Spatial Attention at 8 Weeks	88.07; 77.5	0.00005 sig
PRIMARY Change in Saccadic Eye Movements at 8 Weeks	59.4	0.018 sig

Eligibility Criteria

Inclusion Criteria

Participant has a diagnosis of Autism Spectrum Disorder (on Diagnostic and Statistical Manual -IV, Autism Diagnostic Observation Schedule, Autism Diagnostic Interview-Revised)
Participant has a nonverbal Intelligence Quotient (IQ) of 85 or greater and verbal IQ of 70 or greater
Cooperative and able to follow instructions
Normal hearing acuity
Normal or corrected-to-normal vision

Exclusion Criteria

Major medical or neurological problems including seizures, diagnosed epileptiform EEG abnormalities, migraine, tuberous sclerosis, fragile X, static encephalopathies resulting from prior Central Nervous System insults, significant premature birth, and history of exposure to teratogens, metabolic abnormalities, and history of head trauma, cerebral palsy, stroke, meningitis, brain tumor or additional psychiatric diagnoses
Participants currently participating in vision therapy will be excluded

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02403817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.